BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma

HUTCHMED's Fruquintinib NDA Accepted in China for 2nd-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | News

Bridge Bio Announces First Patient Dosed in Phase 2a Trial of BBT-877 for Idiopathic Pulmonary Fibrosis Treatment

In the Phase 1 study in 2019, BBT-877, a potent autotaxin (ATX) inhibitor, demonstrated its ability to inhibit lysophosphatidic acid (LPA) production by as...

April 13, 2023 | News

Biosyngen received China NMPA IND approval for its T-cell redirection therapy targeting EBV-positive Lymphoma

Currently, commercially available cell therapies, such as CD19 CAR-T, are designed for the treatment of B cell lymphoma or acute lymphoblastic leukemia. Tr...

April 12, 2023 | News

Thermo Fisher Scientific Expands in France for Enhanced Manufacturing Capabilities.

Thermo Fisher Scientific, the world leader in serving science, is adding early development work for oral solid dose therapies to its Bourgoin, France site,...

April 06, 2023 | News

Singapore HSA Accepts Everest Medicines' Nefecon Application for IgA Nephropathy Treatment

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commerc...

April 06, 2023 | News

Bridgewest completes acquisition of sterile injectable manufacturing plant in Western Australia from Pfizer

The newly acquired facility is a cGMP manufacturing plant that produces a wide variety of high quality sterile injectable drug products. The site and ...

April 04, 2023 | News

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model

According to the company's explanation, bacteriophages have been mainly used for R&D on bacterial infectious diseases, but recently the scope of applic...

April 04, 2023 | News

Antengene Doses First Patient with ATG-022 for Advanced Solid Tumors in Australia

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antig...

March 29, 2023 | News

Curia Collaborates with Corning to Advance Biopharmaceutical Continuous-Flow Development and Manufacturing Programs

Curia, a leading contract research, development and manufacturing organization, today announced a collaboration with Corning Incorporated to expand and acc...

March 27, 2023 | News

Daewoong Pharma's Envlo files for product license in three ASEAN countries to enter global market

Submitted an NDA to Indonesia, Philippines and Thailand Signed the export contract in Brazil and Mexico in last ...

March 23, 2023 | News

Connect Biopharma's CBP-201 demonstrates swift relief of Atopic Dermatitis symptoms in pivotal study in China

Stage 1 of ongoing 52-week China pivotal AD trial met primary and secondary endpoints No efficacy plateau at Week 16 In the study “CBP-201, a n...

March 20, 2023 | News

Servier's Phase 3 INDIGO trial shows positive results for vorasidenib in IDH-mutant Glioma

Clinically meaningful achievement of primary and secondary endpoints is first major advance in treatment of low-grade glioma in more than 20 years Endpo...

March 15, 2023 | News

Estrella Biopharma's ARTEMIS® T Cell Therapy EB103 IND Cleared by FDA for B-Cell Lymphomas Clinical Trial

Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transfo...

March 09, 2023 | News

JW Therapeutics Starts Clinical Trial of Carteyva® for High-Risk Large B-Cell Lymphoma

High-risk large B-cell lymphoma includes large B-cell lymphoma with International Prognostic Index (IPI) score ≥3, and high-grade B-cell lymphoma (HGBL)...

March 09, 2023 | News

Stay Connected